GLP-1 Drugs at Two Years: A Public Health Audit
Two years after GLP-1 receptor agonists went from diabetes drugs to cultural phenomena, we audit the public data — CDC prescription trends, NEJM outcomes trials, and the second-order effects showing up in retail and payer numbers.